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Introduction: Cerebellar glioblastoma is an uncommon adult lesion. The pathogeny and prognosis of cerebellar
glioblastoma are still incompletely elucidated.
Case presentation: We report the case of a 19-year-old Moroccan woman. A neurologic examination revealed the
presence of cerebellar signs. A diagnosis of cerebellar glioblastoma is rarely made before surgery. An encephalic
computer tomography scan and magnetic resonance imaging increased the accuracy of defining the nature of the
lesion. Magnetic resonance imaging showed a heterogeneously enhancing mass in the vermis and the right
cerebellar hemisphere. After surgery, glioblastoma was histologically confirmed. Post-operative radiotherapy
followed. The outcome of our patient was favorable after one year of follow-up.
Conclusions: We report an unusual case of cerebellar gliobastoma. Cerebellar glioblastoma multiforme should be
considered in the differential diagnosis of a cerebellar mass lesion.
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Glioblastoma multiforme (GBM) is the most common pri-
mary brain tumor in adults. It usually affects the cerebral
hemispheres, and the peak age of onset is the sixth or sev-
enth decade of life [1]. Cerebellar glioblastoma is a rare
adult tumor. To the best of our knowledge, only a few
cases have been reported [2,3]. The tumor represents 0%
to 3.4% of primary GBMs [4,5]. In this case report, we
present a case of primary cerebellar glioblastoma and dis-
cuss the physiopathology, clinical presentation, diagnosis,
treatment, and general outcomes of this disease.
Case presentation
A 19-year-old Moroccan woman without any other
medical history was admitted to our hospital with a two-
month history of intracranial pressure with nausea, vomit-
ing, and headache. A neurologic examination showed
cerebellar signs, including cerebellar ataxia, dysmetria,
and dysdiadochokinesia. The fundus oculi showed bilat-
eral papillary edema. A cerebral computed tomography* Correspondence: adilhossini@gmail.com
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reproduction in any medium, provided the or(CT) scan showed two lesions: one in the right cerebellar
hemisphere and the other in the vermis. The lesions were
spontaneously hypodense with a peripheral heterogeneous
enhancement after contrast injection and mass effect on
the fourth ventricle (Figures 1 and 2). Cranial magnetic
resonance imaging (MRI) showed irregular contours of
mass lesions. The processes were heterogeneous on T1-
and T2-weighted images and this can be related to a sub-
acute intratumoral hemorrhage with discrete surrounding
edema. After gadolinium was administered, the lesion was
3×4cm in size and had heterogeneous ring enhancement
and a central necrotic area (Figures 3, 4, and 5).
Our patient first had a ventriculoperitoneal shunt. On
the second day, a suboccipital craniotomy was performed
while our patient was in the prone position. After open-
ing of the dura mater and corticectomy, the lesion was
white, infiltrative, crumbly, and not very hemorrhagic,
had no planes of cleavage, and had indistinct margins
from adjacent normal white matter. A subtotal tumor re-
section was performed. A histopathological examination
revealed a cellular tumor, which was consistent with glio-
blastoma (that met the World Health Organization
criteria of grade 4 astrocytoma) and which was composed
of elongated spindle-shaped cells with irregular,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Cerebral computed tomography scan of two lesions in
the right cerebellar hemisphere and the vermis (arrow). The
lesions are spontaneously hypodense.
Figure 2 Vermis and right cerebellar lesions (arrow) with a
peripheral heterogeneous enhancement after contrast injection
and mass effect on the fourth ventricle.
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tive blood vessels and necrosis (hematoxylin and eosin
stain (HES) ×100 and HES ×400). Immunohistochemistry
was accomplished by means of the 3-amino-9-ethylcarba-
zole (AEC) peroxydase method and antigenic restoration,
showing a marking of tumor cells with anti-GFAP (anti-
glial fibrillary acidic protein) antibodies (Figures 6 and 7).
The post-operative course was uneventful, and the
neurologic signs gradually improved. Our patient
received post-operative radiotherapy to the posterior
cranial fossa. There was no tumor recurrence after 12
months.
Discussion
Glioblastoma, the most frequent tumor among all pri-
mary tumors of the central nervous system in adults,
has a frequency of 50% [2,3,5]. Adult cerebellar glioblast-
oma is extremely rare, accounting for 0.24% to 3.8% of
all intracranial glioblastomas [2-4,6,7]. From 1975 to
2011, 170 articles and abstracts about cerebellum glio-
blastoma were published, according to a search of the
Medline database. The male-to-female ratio is 2:1 [8].
Cerebellar glioblastoma can be seen in all age groups.
About 70% of lesions were seen in adults, and median
age was 46.7 years; 30% were noted in children, and me-
dian age was 10.4 years [4,8]. As with our patient,localization is generally median or paramedian with a
possible extension to the fourth ventricle [4]. The tumor
is infiltrative and usually is localized in the deep white
matter [6].
The pathogeny and prognosis of cerebellar glioblast-
omas are still incompletely elucidated because of their
rarity [6]. Most authors have failed to fully explain the
rarity of cerebellar GBM [1,4]. Based on the clinical and
genetic data, there are two subsets of GBM [9]. Glio-
blastoma may develop de novo (primary type) or from
previous low-grade astrocytomas (secondary type) [10].
Secondary glioblastomas develop more frequently in
younger patients and often contain TP 53 mutation
(65%), whereas primary glioblastomas affect mostly eld-
erly patients and generally are characterized by the loss
of heterozygosity 10 q (LOH 10q) (70%), epidermal
growth factor receptor amplification (36%), and TP 53
mutation at a frequency of lower than 30% [10]. Radio-
therapy was also incriminating for the possibility of ana-
plasic progression of mature cerebellar astrocytic cells
[6,11]. Maat-Schieman et al. [11] reported a case of ver-
mis cerebellar astrocytoma that developed after radio-
therapy for craniopharyngioma. Other authors reported
the development of glioblastoma after radiotherapy for
pilocytic astrocytoma, medulloblastoma, and other
Figure 4 The processes are heterogeneous on a T2-weighted
image (arrow) with discrete surrounding edema. The cerebellar
lesion measures 3×4cm in size.
Figure 3 Cranial magnetic resonance imaging of irregular
contours of the mass lesions that are in contact with the fourth
ventricle and the confluence of sinus (arrow). The processes are
heterogeneous on T1-weighted imaging.
Figure 5 The lesions have a heterogeneous contrast ring
enhancement with intratumoral necrotic central zones (arrow).
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of radiotherapy.
Symptomatology of cerebellar glioblastoma, like that
of any other cerebellar tumor, generally includes head-
ache, gait disturbance, vertigo, nausea, vomiting, and
ataxia (as in our case). Indeed, dizziness, neck pain, and
mental confusion can be present [2,4,7]. These symp-
toms are nonspecific and can occur in many diseases.
The diagnosis of cerebellar glioblastoma is rarely made
before surgery, even though CT scan and especially MRI
have increased the accuracy of defining the nature of the
lesion [2,3,6]. MRI shows decreased T1- and increased
T2-weighted signal intensities compared with white mat-
ter. In the majority of cases, a peripheral heterogeneous
enhancement after contrast injection, irregular contours,
and a central necrosis similar to that of supratentorial
glioblastoma are noted. Intratumoral hemorrhage is sug-
gested by mixed signals on T1- and T2-weighted signals
[2,3,6]. MRI diffusion/perfusion and MRI spectroscopy
examinations can also facilitate the characterization of
the lesions and the differential diagnosis [2].
Proton spectroscopy of high-grade gliomas shows a
significant reduction in NAA (N-acetyl aspartate), owing
to the loss in neuronal elements, and a choline peak
Figure 6 Original coloration shows an intense cellular density.
The cells are characterized by a marked anisokaryosis. The nuclei are
quite large. The cells have an abundant and eosinophilic cytoplasm
(arrow). Numerous mitoses are observed. Stain: hematoxylin and
eosin; magnification: ×400.
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The presence of a lactate peak correlates with tumor
hypoxia [2,3,6,13]. Hydrocephalus was reported in our
patient and also in other cases. It was found in four out
of nine patients of Kuroiwa et al. [4].
Cerebellar metastases are the most frequent posterior
cerebral fossa tumors for adults and represent the most
common differential diagnosis, particularly if the lesion
is solitary and there is no history of primary lesion
[2,4,6]. However, the margins of metastases are distinct
with a most important surrounding edema. Metastasis
may demonstrate cystic components or show hypointen-
sity on T2-weighted images, suggesting intratumoral
hemorrhage, calcification, or mucinous components,
while GBM grows infiltratively with peripheral heteroge-
neous enhancement and poorly defined margins [4].
Peritumoral edema is rather mild compared with that ofFigure 7 Immunohistochemistry study by 3-amino-9-
ethylcarbazole peroxidase method and antigenic restoration in
warmth show a labeling of the cells with the anti-GFAP (anti-
glial fibrillary acidic protein) antibodies. The positivity of the
GFAP confirmed the astrocytic nature of the lesion (arrow). An
immunohistochemistry profile of glioblastoma is shown.metastatic tumors [1,7]. Intratumoral hemorrhage is
common, but calcification or cystic components are
rarely seen.
Diagnostic difficulty also arises when there are several
lesions, as with our patient. Other causes like abscesses,
granulomas, or metastases should be considered, also
primitive neuroectodermal tumor of the posterior fossa,
medulloblastoma, ependymoma, pilocytic astrocytoma,
or hemangioblastoma [1,2,4]. As the posterior fossa is a
small compartment, it is very difficult to be absolutely
certain that these two lesions were completely distinct.
They were probably two focal areas of tumor connected
with each other. As it was not possible to resect both
lesions, there was no evidence to prove the true multi-
focal nature of this tumor.
The treatment of cerebellar glioblastoma is usually pal-
liative and encompasses surgery, radiotherapy, and
chemotherapy [1]. The decision regarding surgery for
glioblastoma depends on the patient’s age, performance
status, proximity to “eloquent” areas of brain, feasibility
of decreasing the mass effect, resectability of the tumor,
and, in a patient with recurrent disease, the time since
previous surgery. Surgical treatment includes stereotac-
tic or open biopsy and debulking with subtotal or gross
resection. Surgery will achieve a diagnosis, decrease
intracranial pressure, increase survival, and reduce the
need for corticosteroid therapy [1,3,4].
After surgery, the patient can be treated with fractio-
nated external beam radiotherapy [3,7]. Total doses of
54 to 60Gy in 1.8 to 2.0Gy fractions are administered to
the gross tumor volume [1]. Craniospinal irradiation can
be recommended for children because of the high inci-
dence of cerebrospinal fluid dissemination of cerebellar
GBM [7]. The chemotherapy of choice is temozolomide,
although bis-chloronitrosourea, lomustine, or PCV (pro-
carbazine, lomustine, vincristine) can also be used [14].
Patients with a good performance score should be trea-
ted with daily temozolomide (75mg/m2) administered
with post-operative radiation therapy followed by one
year of a dose of 150 to 200mg/m2 per day for five days
each month [15].
The biological behaviors of cerebellar and supratentor-
ial GBM are similar. On the other hand, the prognosis of
cerebellar glioblastoma for younger patients is similar to
that of anaplasic astrocytoma and probably has a better
outcome than cerebral glioblastoma [3]. The mean sur-
vival of cerebellar glioblastoma after the beginning of
the symptomatology has been reported to be approxi-
mately 12 to 19 months [3,7,8].
Conclusions
Cerebellar GBM is rare and should be considered in the
differential diagnosis of a cerebellar mass lesion. MRI
can facilitate the characterization of the lesions and the
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gressive surgical treatment along with radiation therapy
remains the established management strategy.
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